FLORONE E Drug Patent Profile

Which patents cover Florone E, and what generic alternatives are available?

Florone E is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in FLORONE E is diflorasone diacetate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the diflorasone diacetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Florone E

A generic version of FLORONE E was approved as diflorasone diacetate by AVONDALE PHARMS on April 27^th, 1999.

Summary for FLORONE E

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	56
Patent Applications:	8,455
DailyMed Link:	FLORONE E at DailyMed

US Patents and Regulatory Information for FLORONE E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	FLORONE E	diflorasone diacetate	CREAM;TOPICAL	019259-001	Aug 28, 1985		DISCN	No	No

Expired US Patents for FLORONE E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	FLORONE E	diflorasone diacetate	CREAM;TOPICAL	019259-001	Aug 28, 1985	3,980,778

International Patents for FLORONE E

See the table below for patents covering FLORONE E around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	197216	PROCEDIMIENTO PARA PRODUCIR 17,21-DIACETATO DE 6ALPHA,9ALPHA-DIFLUORO-11BETA,17,21-TRIHIDROXI-16BETA-METIL-PREGNA-1,4-DIEN-3,20-DIONA
Australia	468257
Australia	5257973
Belgium	796560

Last updated: April 25, 2026

FLORONE E: What do market dynamics and the financial trajectory indicate?

FlORONE E is a proprietary pharmaceutical product name, but no drug-specific market, pricing, revenue, sales volume, regulatory, or patent-prosecution record is provided in the input. With no hard data tied to the specific product (active ingredient, dosage form, strength, label country, MAH/holder, launch year, channel mix, or observed sales history), a complete, accurate market and financial trajectory analysis cannot be produced without introducing unverifiable assumptions.

No actionable findings can be stated.

What market dynamics drive FLORONE E?

No drug-specific dynamics can be quantified because the product is not identified by its regulated attributes (active ingredient(s), strength, formulation, route, and marketing authorization geography). Without those anchors, there is no defensible mapping to:

• competitive landscape (same-molecule generics, biosimilars where applicable, and class substitutes),
• reimbursement environment (formulary status, HTA outcomes, tender dynamics),
• supply risks (API source concentration, manufacturing site constraints),
• uptake curve drivers (hospital vs retail channel behavior, guideline inclusion),
• pricing pressure (originator vs generic erosion, parallel imports, price freezes).

How does the financial trajectory for FLORONE E look?

A financial trajectory requires at minimum one of: reported sales, shipment volumes, prescriptions, net pricing, payer coverage changes, or financial disclosures by the marketing authorization holder. None is provided, and FLORONE E cannot be reliably linked to a specific publicly reported product line.

Key risk and opportunity map for FLORONE E

No product-linked patent or exclusivity status is provided, so no defensible view can be made on:

• expected revenue durability under patent expiry,
• litigation overformulary or ANDA-type entries,
• orphan exclusivity, pediatric extensions, data exclusivity, or market protection windows,
• switching dynamics post-first generic entry.

---

Key Takeaways

• FLORONE E cannot be analyzed for market dynamics or financial trajectory on the information provided.
• A credible analysis requires product identity and observed market metrics; neither is included in the input.

---

FAQs

1. What is FLORONE E’s active ingredient and strength?
   Not provided, so no product-specific analysis is possible.

2. Where is FLORONE E marketed (country/region) and who is the marketing authorization holder?
   Not provided.

3. What is FLORONE E’s current competitive environment (generics or substitutes)?
   Not provided.

4. Is FLORONE E protected by patents or exclusivity, and when do they expire?
   Not provided.

5. What revenue and volume indicators exist for FLORONE E (sales, prescriptions, pricing)?
   Not provided.

---

References

No sources were cited because no cited, product-specific information was provided in the prompt.